MedTrace Logo

VS-6766+Abema+Fulv in Met HR+/HER- BC

NCT05608252 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2026-04-30

No results posted yet for this study

Summary

This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer.

The names of the study drugs involved in this study are:

* VS-6766
* Abemaciclib
* Fulvestrant

Conditions

Interventions

DRUG

VS-6766

Taken Orally

DRUG

Abemaciclib

Taken Orally

DRUG

Fulvestrant

Administered by intramuscular injection

Sponsors & Collaborators

  • Verastem, Inc.

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Adrienne G. Waks

    lead OTHER

Principal Investigators

  • Adrienne G Waks, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-23
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05608252 on ClinicalTrials.gov